# US 2022/0031683 A1 · Compositions and kits for omeprazole suspension

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031683 A1
- Document ID: US20220031683A1
- Status: Published application
- Kind: A1
- Application number: 17/463,258
- Filed: 2021-08-31
- Published: 2022-02-03
- Earliest claimed: 2019-07-16
- Assignees: Azurity Pharmaceuticals, Inc.
- Applicants: Azurity Pharmaceuticals, Inc.
- Inventors: Zeus PENDON; Steven Dinh
- Web page: https://patentgrep.com/patent/US20220031683A1

## CPC

- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/0095: {Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/10: Dispersions; Emulsions
- A61K 31/351: not condensed with another ring
- A61K 47/02: Inorganic compounds
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/20: containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A61K 47/24: containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61K 47/38: Cellulose; Derivatives thereof
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Disclosed herein are liquid diluents, formulations, and kits for preparing reconstituted suspensions of a proton pump inhibitor (e.g., omeprazole). The present disclosure also provides formulations for liquid diluents that do not have a tendency for gel formation following exposure to freeze-thaw cycles.

## Claims

### Claim at position 1

-17. (canceled)

### Claim 18

A suspension of a proton pump inhibitor consisting essentially of:
a proton pump inhibitor;
poloxamer;
a suspending agent, wherein the suspending agent is (i) sodium carboxymethylcellulose (CMC) or (ii) a combination of sodium CMC and microcrystalline cellulose;
an acid neutralizing agent;
a defoamer;
a preservative;
water;
optionally a buffer that maintains a pH of 8 to 9.5; and
optionally one or more selected from a sweetener, a coloring agent, and a flavoring agent;
wherein the suspension is homogenous and stable for at least 30 days at ambient conditions and at refrigerated temperature conditions.

### Claim 19 (depends on 18)

The suspension of claim 18, wherein the poloxamer has a number average molecular weight of about 7000 to about 10,000 Da and an ethylene glycol content of about 80 wt % to about 85 wt %.

### Claim 20 (depends on 18)

The suspension of claim 18, wherein the poloxamer is poloxamer 188 and is present in the suspension at 1.0%-4.0% w/v.

### Claim 21 (depends on 18)

The suspension of claim 18, wherein the sodium CMC is present in the suspension at 1.0%-2.0% w/v.

### Claim 22 (depends on 18)

The suspension of claim 18, wherein the suspending agent is a combination of sodium CMC and microcrystalline cellulose.

### Claim 23 (depends on 18)

The suspension of claim 18, wherein the preservative is benzyl alcohol.

### Claim 24 (depends on 18)

The suspension of claim 18, wherein the preservative is one or more of the group consisting of: benzyl alcohol, ascorbic acid, ascorbyl palmitate, BHA, BHT, citric acid, sodium benzoate, benzoic acid, sodium bisulfate, sodium metabisulfite, sodium sulfite, parabens, potassium sorbate, vanillin, and pharmaceutically acceptable salts thereof.

### Claim 25 (depends on 18)

The suspension of claim 18, wherein suspension comprises a sweetener that is glucose, fructose, sucrose, xylitol, maltodextrin, polydextrose, glycerin, inulin, maltol, salts of acesulfame, alitame, aspartame, neotame, cyclamate salts, sucralose, sorbitol, saccharin and its salts, or a combination thereof.

### Claim 26 (depends on 18)

The suspension of claim 18, wherein the suspension comprises a buffer that is selected from sodium citrate, sodium bicarbonate, or a combination thereof.

### Claim 27 (depends on 18)

The suspension of claim 18, wherein the acid neutralizing agent is sodium bicarbonate.

### Claim 28

A kit consisting essentially of:
a first container having a 100% w/w powder of a proton pump inhibitor (PPI);
a second container having a liquid diluent consisting essentially of poloxamer,
a suspending agent, wherein the suspending agent is (i) sodium carboxymethylcellulose (CMC) or (ii) a combination of sodium CMC and microcrystalline cellulose,
an acid neutralizing agent,
a defoamer,
a preservative,
water,
optionally a buffer that maintains a pH of 8 to 9.5, and
optionally one or more selected from a sweetener, a coloring agent, and a flavoring agent;
wherein the liquid diluent is stable for at least 30 days at 5±3° C. and is resistant to gel formation for at least one freeze-thaw cycle,
wherein the first and second containers are of a size such that the PPI powder and liquid diluent can be combined in either the first or second container to produce a reconstituted PPI suspension; and
wherein the reconstituted PPI suspension is homogenous and stable for at least 30 days at ambient and refrigerated temperature conditions.

### Claim 29 (depends on 28)

The kit of claim 28, wherein the percentage of PPI omeprazole powder dissolved to make the reconstituted PPI suspension is >80% by dissolution assay after 5 minutes of mixing.

### Claim 30 (depends on 28)

The kit of claim 28, wherein the poloxamer is present in the reconstituted PPI suspension at 1.0%-4.0% w/v, and the sodium CMC is present in the reconstituted PPI suspension at 1.0%-2.0% w/v.

### Claim 31 (depends on 28)

The kit of claim 28, wherein the liquid diluent comprises:
1.0%-4.0% w/v poloxamer;
1.0%-5.0% w/v of a suspending agent, wherein the suspending agent is (i) sodium carboxymethylcellulose (CMC) or (ii) a combination of sodium CMC and microcrystalline cellulose;
8.0%-8.8% w/v of an acid neutralizing agent;
0.1%-0.3% w/v of a defoamer;
0.2%-1.2% w/v of a preservative;
water;
optionally a buffer that maintains a pH of 8 to 9.5; and
optionally one or more selected from a sweetener, a coloring agent, and a flavoring agent.

### Claim 32 (depends on 22)

The suspension of claim 22, wherein the combination of sodium CMC and microcrystalline cellulose is present in the liquid diluent at about 4.0% w/v.

### Claim 33 (depends on 18)

The suspension of claim 18, wherein the defoamer is simethicone emulsion.

### Claim 34 (depends on 23)

The suspension of claim 23, wherein the benzyl alcohol is present at about 0.4% to about 0.6% w/v in the suspension.

### Claim 35 (depends on 18)

The suspension of claim 18, wherein the suspension comprises a buffer.

### Claim 36 (depends on 35)

The suspension of claim 35, wherein the buffer is one or more of a citrate, tartrate, acetate, carbonate, phosphate, metaphosphate, glycerophosphate, polyphosphate, and pyrophosphate.

### Claim 37 (depends on 18)

The suspension of claim 18, wherein the proton pump inhibitor is omeprazole or lansoprazole.

### Claim 38 (depends on 18)

The suspension of claim 18, wherein the proton pump inhibitor is omeprazole and is present in the suspension at about 2 mg/ml.

### Claim 39 (depends on 28)

The kit of claim 28, wherein the proton pump inhibitor is omeprazole or lansoprazole.
